Two approaches to the design of very active and highly selective delta opioid peptides were used to obtain new deltorpin analogs with altered hydrophobic and stereoelectronic properties. Deltorphin I and II analogs were synthesized involving the substitution of Ile instead of Val at positions 5 and 6 in the address domain and 2-aminotetralin-2-carboxylic acid (Atc) instead of Phe in the message domain. The peptides were agonists in the subnanomolar range in the MVD assay and in the micromolar or higher range in the GPI assay, showing a very high selectivity for delta receptors. A very similar trend could be observed in radioreceptor binding assays in which selective tritiated opioid ligands were used. (R)- and (S)-Atc-deltoriphins exhibited similar Ki values in the binding assay, with almost complete loss of the stereospecificity of the binding. Conformational studies provided evidence for the little disturbance of the backbone conformational equilibrium when Phe3 is replaced by (S)- or (R)-Atc. The use of the Atc constraint gives additional evidence that, during its interaction with the delta receptor, the side chain of residue 3 adopts the trans conformation at chi 1.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm9602726DOI Listing

Publication Analysis

Top Keywords

deltorphin analogs
8
2-aminotetralin-2-carboxylic acid
8
conformationally constrained
4
constrained deltorphin
4
analogs 2-aminotetralin-2-carboxylic
4
acid position
4
position approaches
4
approaches design
4
design active
4
active highly
4

Similar Publications

Opiate alkaloids and their synthetic derivatives are still widely used in pain management, drug addiction, and abuse. To avoid serious side effects, compounds with properly designed pharmacological profiles at the opioid receptor subtypes are long needed. Here a series of 17-N-substituted derivatives of normorphine and noroxymorphone analogues with five- and six-membered ring substituents have been synthesized for structure-activity study.

View Article and Find Full Text PDF

Several studies have proposed δ opioid receptors as influential targets for developing novel antidepressants. Deltorphin (DLT) and deltorphin II (DLT-II) have high affinity and selectivity for δ opioid receptors; thus, it is likely that DLT analogs possess antidepressant-like effects. Based on this, we evaluated the effects of four DLT analogs (DLT-related synthetic peptides) on immobility behavior in the tail suspension test.

View Article and Find Full Text PDF

In previous work we evaluated an opioid glycopeptide with mixed μ/δ-opioid receptor agonism that was a congener of leu-enkephalin, MMP-2200. The glycopeptide analogue showed penetration of the blood-brain barrier (BBB) after systemic administration to rats, as well as profound central effects in models of Parkinson's disease (PD) and levodopa (L-DOPA)-induced dyskinesia (LID). In the present study, we tested the glycopeptide BBI-11008 with selective δ-opioid receptor agonism, an analogue of deltorphin, a peptide secreted from the skin of frogs (genus ).

View Article and Find Full Text PDF

Identification of ex vivo catabolites of peptides with doping potential in equine plasma by HILIC-HRMS.

Drug Test Anal

June 2020

Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, New Bolton Center Campus, Kennett Square, PA, USA.

Bioactive peptides pose a great threat to sports integrity. The detection of these peptides is essential for enforcing their prohibition in sports. Identifying the catabolites of these peptides that are formed ex vivo in plasma may improve their detection.

View Article and Find Full Text PDF

New opioid receptor antagonist: Naltrexone-14-O-sulfate synthesis and pharmacology.

Eur J Pharmacol

August 2017

Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, P.O. Box 370, H-1445 Budapest, Hungary. Electronic address:

Article Synopsis
  • Opioid antagonists like naloxone and naltrexone are commonly used in medicine and can cross the blood-brain barrier; modifying their structure (like with methylnaltrexone) reduces this ability.
  • The study introduces naltrexone-14-O-sulfate, a zwitterionic compound, and assesses its pharmacological properties, finding it has better selectivity for opioid receptors compared to naltrexone and naloxone, even though it has a lower binding affinity.
  • Naltrexone-14-O-sulfate was shown to effectively counteract morphine's effects in mouse models, suggesting unexpected central nervous system (CNS) penetration, prompting the need for further research on its
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!